0.421  -0.079 (-15.8%)		03-05 16:00
Open: 0.421 High: 0.4211 Volume: 2,295		Pre. Close: 0.5 Low: 0.421 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.59	1-year :	0.69
Resists	First :	0.5	Second :	0.59
Pivot price	0.44
Supports	First :	0.34	Second :	0.25
MAs	MA(5) :	0.46	MA(20) :	0.43
	MA(100) :	1.42	MA(250) :	2.73
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	86.2	D(3) :	87.2
RSI	RSI(14): 42.3
52-week	High :	14.27	Low :	0.25

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTIX ] has closed above bottom band by 37.0%. Bollinger Bands are 79.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.42 - 0.42	0.42 - 0.43
Low:	0.41 - 0.42	0.42 - 0.42
Close:	0.42 - 0.42	0.42 - 0.43

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Tue, 24 Feb 2026
Protagenic Therapeutics Unwinds Phytanix Deal and Settles Litigation - TipRanks

Tue, 09 Dec 2025
Protagenic Therapeutics (PTIX) Shares Phase 1 Study Results for PT00114 - GuruFocus

Thu, 27 Nov 2025
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Livingston Daily

Fri, 22 Aug 2025
Biotech Protagenic Therapeutics Working to Maintain Nasdaq Compliance After Merger-Related Filing Delay - Stock Titan

Thu, 21 Aug 2025
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders - ACCESS Newswire

Thu, 21 Aug 2025
Protagenic Therapeutics Stock Leaps: A Moment to Ponder? - timothysykes.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	0 (M)
Held by Insiders	3.5 (%)
Held by Institutions	6.9 (%)
Shares Short	62 (K)
Shares Short P.Month	57 (K)

EPS	-13.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.44
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.04
PEG Ratio	0
Price to Book value	-0.18
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.